Post-Transplantation Lymphoproliferative Disorders in Adults

N Engl J Med. 2018 Feb 8;378(6):549-562. doi: 10.1056/NEJMra1702693.

Authors

Daan Dierickx¹, Thomas M Habermann¹

Affiliation

¹ From the Department of Hematology, University Hospitals Leuven, and the Laboratory for Experimental Hematology, Department of Oncology, University of Leuven, Leuven, Belgium (D.D.); and the Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN (T.M.H.).

PMID: 29414277
DOI: 10.1056/NEJMra1702693

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Adult
Epstein-Barr Virus Infections / complications
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Immunocompromised Host*
Immunologic Factors / therapeutic use
Immunosuppression Therapy / adverse effects*
Immunotherapy
Lymphoproliferative Disorders / diagnosis
Lymphoproliferative Disorders / epidemiology
Lymphoproliferative Disorders / etiology*
Lymphoproliferative Disorders / therapy
Organ Transplantation / adverse effects*
Prognosis
Risk Factors
Rituximab / therapeutic use
Transplantation, Homologous

Substances

Immunologic Factors
Rituximab